Dr. Gottlieb is an internationally recognized expert in the field of psoriasis and psoriatic arthritis. Her research uses targeted immunobiologics as pathogenic probes, providing new understanding of the pathogenesis of psoriasis and providing the foundation for biologic drug development in these two debilitating diseases. Through a study she had published in Lancet in 2001, Dr. Gottlieb was the first to show the efficacy of TNF blockers as monotherapy for moderate to severe psoriasis. Her research led to multiple TNF blockers being FDA-approved for psoriasis which revolutionized the care of psoriasis and psoriatic arthritis patients. In addition, Dr. Gottlieb was one of the first scientists to demonstrate that psoriasis is a T cell mediated disease. She showed that treatment with a T cell-specific immunotoxin cleared psoriasis clinically and histologically.